Press Release Description

Increasing Cases of Genetic Mutations Worldwide are Driving the Acute Myeloid Leukemia (AML) Market

A recent research report published by MarkNtel Advisors states that the Global Acute Myeloid Leukemia (AML) Market is expecting around 13% CAGR during 2022-27. The global rise in the geriatric population, i.e., more prone to cancers & other critical diseases, and the mounting prevalence of genetic mutations are projected to drive the market during 2022-27. These aspects have resulted in the globally expanding pool of patients suffering from AML. As a result, several pharma companies in different countries are substantially investing in the development of new drugs for AML treatment.

Moreover, there are various ongoing research activities in the field of oncology, along with healthcare infrastructural developments worldwide. More and more combination & targeted therapies are being adopted extensively across different corners of the world for the treatment of patients with AML or other severe malignancies. Hence, the facts cited above indicate profitable prospects for the overall market growth through 2027, further states the research report, “Global Acute Myeloid Leukemia (AML) Market Analysis, 2022.”

Chemotherapy to Remain the Preferred AML Treatment through 2027

Globally, chemotherapy is the first-line treatment provided to patients suffering from Acute Myeloid Leukemia. It involves the dosage of Cytarabine & Anthracyclines like Cerubidine (daunorubicin) or Idamycin (idarubicin).

Of both chemo drugs, Cytarabine has shown significant efficacy in AML treatment, coupled with high survival of patients, and therefore, would continue its dominance in the Global Acute Myeloid Leukemia (AML) Market through 2027.

Moreover, Cytarabine possesses greater tolerance when combined with other drugs. With these characteristics, more & more pharma firms are obtaining rapid approvals by regulatory authorities like FDA to use Cytarabine in the chemo treatment of newly-diagnosed AML-MRC patients globally.

With Rising Drug Approvals for AML Treatment, North America to Continue Dominating the Market

Countries like the US & Canada have a well-established healthcare infrastructure and are witnessing a growing patient pool of acute myeloid leukemia & the rising elderly population. As a result, there's a mounting requirement for advanced targeted therapies to treat patients suffering from AML, owing to which massive investments by both governments & pharmaceutical companies in the development of pipeline drugs are being observed.

Hence, more & more people becoming aware of various AML treatments available across these countries is leading to the burgeoning demand for AML therapeutic products across North America, which, in turn, is driving the regional market.

In addition, the extensive presence of major pharma companies and rapid drug approvals for AML treatment would further lead North America to dominate the Acute Myeloid Leukemia (AML) Market globally in the years to come.

Competitive Landscape

The leading companies operating in the Global Acute Myeloid Leukemia (AML) Market include AstraZeneca PLC, AbbVie Inc., Baxter International Inc., Bayer AG, Bristol Myers Squibb, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, Pfizer Inc., & Sanofi S.A., among others.

Key Questions Answered in the Research Report

  1. What are the current & future trends in the Global Acute Myeloid Leukemia (AML) Market?
  2. How has the industry been evolving in terms of geography & product adoption?
  3. How has the competition been shaping across various regions, followed by their comparative factorial indexing?
  4. What are the key growth drivers & challenges for the Global Acute Myeloid Leukemia (AML) Market?
  5. What are the customer orientation, purchase behavior, & expectations from the prominent players in the Global Acute Myeloid Leukemia (AML) Market?

Market Segmentation:

  1. By Diagnosis (Blood Tests, Bone Marrow Biopsy, Imaging, Lumbar Puncture (Spinal Tap))
  2. By Treatment (Chemotherapy (Cytarabine, Anthracycline, Others (Cladribine (2-CdA), Fludarabine, etc.)), Targeted Therapy (Midostaurin (Rydapt), Gilteritinib (Xospata), Ivosidenib (Tibsovo), Enasidenib (Idhifa)), Stem Cell Transplant)
  3. By End-User (Hospitals, Specialty Clinics, Others (Ambulatory Surgery Centers, etc.))
  4. By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific)
  5. By Countries (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)